Hemogenyx Pharmaceuticals plc (HEMO.L)
Hemogenyx Pharmaceuticals plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Company Info
Highlights
£12.15M
-£2.00
-£643.37K
-£5.99M
£270.00 - £1,480.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Hemogenyx Pharmaceuticals plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Hemogenyx Pharmaceuticals plc had a return of -16.79% year-to-date (YTD) and -78.70% in the last 12 months.
HEMO.L
-16.79%
-13.82%
-39.04%
-78.70%
-15.04%
N/A
^GSPC (Benchmark)
3.96%
2.77%
10.09%
21.57%
12.62%
11.30%
Monthly Returns
The table below presents the monthly returns of HEMO.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -10.00% | -16.79% | |||||||||||
| 2024 | 45.65% | -42.76% | -8.21% | -11.59% | -5.21% | -11.19% | -1.15% | 1.08% | 23.38% | -16.72% | -16.28% | -10.08% | -55.98% |
| 2023 | 67.92% | 4.49% | -12.90% | 1.23% | 12.20% | -33.48% | -1.96% | 6.67% | 43.75% | -13.04% | 15.00% | -0.00% | 73.58% |
| 2022 | -13.33% | -10.77% | -1.72% | 10.53% | -1.59% | -16.13% | -1.92% | 19.61% | -18.69% | 31.05% | -22.77% | 5.58% | -29.33% |
| 2021 | -22.28% | -10.67% | 5.22% | -62.41% | -30.19% | 24.59% | -19.74% | 9.46% | -4.94% | 0.00% | -10.39% | 8.70% | -80.57% |
| 2020 | -0.00% | -11.54% | -26.09% | 684.31% | -33.50% | -12.03% | 30.77% | 75.16% | -25.75% | -8.54% | -10.44% | 18.40% | 394.87% |
| 2019 | 50.00% | -20.63% | -14.00% | 9.30% | 25.53% | 0.00% | -3.39% | -19.30% | 13.04% | -23.08% | 12.50% | -13.33% | -7.14% |
| 2018 | -10.00% | 86.67% | -35.12% | 11.93% | 27.87% | -10.90% | -15.11% | -11.86% | 7.69% | -10.71% | 2.00% | -17.65% | -16.00% |
| 2017 | 0.00% | 4.76% | -9.09% | -4.76% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HEMO.L is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Hemogenyx Pharmaceuticals plc (HEMO.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Hemogenyx Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Hemogenyx Pharmaceuticals plc was 94.44%, occurring on Dec 18, 2024. The portfolio has not yet recovered.
The current Hemogenyx Pharmaceuticals plc drawdown is 94.15%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.44% | Aug 28, 2020 | 1083 | Dec 18, 2024 | — | — | — |
| -81.82% | Feb 27, 2018 | 527 | Mar 26, 2020 | 21 | Apr 28, 2020 | 548 |
| -49.02% | Apr 29, 2020 | 33 | Jun 16, 2020 | 50 | Aug 25, 2020 | 83 |
| -34.62% | Nov 15, 2017 | 51 | Jan 29, 2018 | 20 | Feb 26, 2018 | 71 |
| -24% | Oct 24, 2017 | 11 | Nov 7, 2017 | 5 | Nov 14, 2017 | 16 |
Volatility
Volatility Chart
The current Hemogenyx Pharmaceuticals plc volatility is 13.19%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Hemogenyx Pharmaceuticals plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |